日本語 
Rentschler Biopharma SE, a leading global CDMO for biopharmaceuticals, is boldly expanding into Japan and South Korea. This move shows a strong commitment to support clients in Asia’s growing biopharma markets. Demand is increasing there. Joining BioProcess International Asia in Kyoto will help the company connect with current and potential partners. This will drive teamwork and solutions to meet changing industry needs.
Rentschler Biopharma’s partnership with Summit Pharmaceuticals International (SPI) boosts its presence in the area. This helps them support clients in both countries. They provide full solutions for developing and making biologics.
CEO Benedikt von Braunmühl highlighted the company’s focus on strong client relationships. He also pointed out their aim to provide high-quality, innovative treatments fast. He highlighted Rentschler Biopharma’s mission: to ensure reliability from idea to market approval. They always push the boundaries of biotherapeutic development. This helps improve patient outcomes.
Also Read: Nxera Pharma to Get $10M from AbbVie for Neuro Project
The company highlights its advanced manufacturing skills at its Japan roadshow. It shows expertise in:
- Cell line development
- Upstream processing
- Downstream processing
- GMP manufacturing
- Analytical testing
- Regulatory affairs
This event emphasizes their strengths in these key areas. The company speeds up the launch of life-saving biologics in Asia with its Rentschler Expression Platform. This ensures quick and efficient delivery to clients.
Rentschler Biopharma is now focusing on Japan and South Korea. This matches the biopharmaceutical innovation goals of both countries. This move expands the company’s global reach. It also strengthens the area’s robust healthcare system.
English